Systemic Sclerosis-Polymyositis Overlap with Inflammatory Myopathy
The bilateral absence of the semimembranosus muscles on MRI most likely represents severe inflammatory myopathy with muscle atrophy secondary to systemic sclerosis-polymyositis overlap syndrome, given the patient's anti-PM-Scl antibody positivity, progressive proximal muscle weakness, and systemic features. 1, 2
Most Plausible Cause
The missing semimembranosus muscles bilaterally represent end-stage muscle damage from chronic inflammatory myopathy in the context of systemic sclerosis-polymyositis overlap. This is not a congenital absence but rather severe atrophy and replacement of muscle tissue due to:
- Anti-PM-Scl antibody-associated myositis: Even transiently positive anti-PM-Scl-75 defines a specific SSc subset with high frequency of myositis (51% vs 14% in antibody-negative patients) and muscle involvement that can be severe 1, 3
- Progressive inflammatory muscle destruction: The 2-3 year history of worsening proximal weakness (difficulty chewing, dysphagia, stair climbing, arm elevation) with burning pain and post-exertional tremor indicates active myositis 4
- Systemic sclerosis overlap features: The combination of Raynaud's phenomenon, puffy fingers, telangiectasia, capillary changes, and elevated ESR with anti-PM-Scl antibodies creates a distinct clinical phenotype with prominent muscle involvement 5, 2
Immediate Next Steps in Evaluation
Laboratory Assessment
- Muscle enzyme levels: Creatine kinase (CK), aldolase, AST, ALT, and LDH to quantify muscle inflammation 4, 6
- Troponin and cardiac evaluation: ECG and echocardiogram or cardiac MRI to exclude myocarditis, which can be life-threatening in inflammatory myopathies 6, 4
- Comprehensive myositis autoantibody panel: Including anti-Jo-1, anti-TIF1γ, anti-NXP2, anti-Mi-2, anti-SRP, and anti-HMGCR to further characterize the myositis subtype 4, 6
- Inflammatory markers: Confirm ESR and add CRP 6
Imaging Studies
- MRI of proximal muscles (thighs, shoulders, paraspinal): Using T1-weighted, T2-weighted, and STIR (short tau inversion recovery) sequences to identify active muscle inflammation, guide biopsy site selection, and assess extent of muscle involvement 4
- High-resolution chest CT: To screen for interstitial lung disease, which occurs in 50% of anti-PM-Scl positive SSc patients and is a major cause of morbidity 1, 2, 3
- Pulmonary function tests: Including DLCO to assess for restrictive lung disease and pulmonary vascular involvement 7
Electrophysiologic and Tissue Studies
- Electromyography (EMG): To demonstrate myopathic changes (polyphasic motor unit action potentials of short duration and low amplitude, fibrillation potentials, sharp waves) and differentiate from neurogenic causes 4
- Muscle biopsy: From an affected muscle identified on MRI (avoiding the semimembranosus given complete absence) to confirm inflammatory infiltrate, assess for necrotizing features, and exclude inclusion body myositis 4, 8
Additional Screening
- Videofluoroscopy or modified barium swallow: Given dysphagia and chewing difficulties to assess cricopharyngeal dysfunction and aspiration risk 4
- Malignancy screening: Anti-PM-Scl antibodies can be associated with overlap syndromes, and dermatomyositis-like features warrant age-appropriate cancer screening 7, 2
Critical Management Considerations
Urgent rheumatology and/or neurology referral is mandatory given the severity of muscle involvement with complete muscle loss 6. The clinical presentation suggests grade 3 myositis (severe weakness limiting self-care activities) requiring:
- High-dose corticosteroids: Prednisone 1 mg/kg/day or methylprednisolone IV if severe compromise 4, 6
- Concurrent steroid-sparing agent: Methotrexate, azathioprine, or mycophenolate mofetil initiated simultaneously to allow corticosteroid taper 4
- Consider IVIG or rituximab: For refractory disease or extensive organ involvement 4
Important Caveats
Anti-PM-Scl positive SSc-myositis overlap may respond to lower corticosteroid doses compared to other inflammatory myopathies 9. However, the severity of muscle loss in this case (complete absence of bilateral semimembranosus) suggests aggressive disease requiring intensive immunosuppression.
Distinguish from inclusion body myositis: The asymmetric distal weakness, finger flexor involvement, and quadriceps atrophy typical of IBM are not described here, but the bilateral semimembranosus absence is unusual and warrants careful pathologic evaluation 4.
Cardiac involvement screening is non-negotiable: Myocarditis in inflammatory myopathies carries high mortality risk and requires immediate identification 6, 4.
The combination of systemic sclerosis features with anti-PM-Scl antibodies and severe progressive myopathy defines a specific high-risk phenotype requiring aggressive multimodal immunosuppression to prevent further irreversible muscle damage and life-threatening complications 1, 2, 3.